Jasper Therapeutics (JSPR) Non-Current Deffered Revenue (2019 - 2021)
Jasper Therapeutics (JSPR) posted quarterly Non-Current Deffered Revenue of $3.5 million for Q2 2021, little changed year-over-year from $3.5 million in Q2 2020, and little changed quarter-over-quarter from $3.5 million in Q1 2021.
Jasper Therapeutics (JSPR) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends
Jasper Therapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $3.5 million for Q2 2021.
- In Q2 2021, Non-Current Deffered Revenue changed 0.0% year-over-year to $3.5 million; the TTM figure through Jun 2021 stood at $3.5 million (changed 0.0% YoY), while the FY2020 annual figure was $3.5 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue for Q2 2021 stood at $3.5 million, roughly flat from $3.5 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $3.5 million in Q4 2019, with the low at $3.5 million in Q4 2019.
- The 3-year median for Non-Current Deffered Revenue is $3.5 million (2019), against an average of $3.5 million.
- Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2020, while the deepest fall reached 0.0% in 2020.
- Jasper Therapeutics' Non-Current Deffered Revenue stood at $3.5 million in 2019, then changed by 0.0% to $3.5 million in 2020, then changed by 0.0% to $3.5 million in 2021.
- Business Quant data shows JSPR's Non-Current Deffered Revenue at $3.5 million in Q2 2021, $3.5 million in Q1 2021, and $3.5 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 3.50 Mn |
| Mar 31, 2021 | 3.50 Mn |
| Dec 31, 2020 | 3.50 Mn |
| Sep 30, 2020 | 3.50 Mn |
| Jun 30, 2020 | 3.50 Mn |
| Mar 31, 2020 | 3.50 Mn |
| Dec 31, 2019 | 3.50 Mn |